Who are Auto-CD34+ cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, cART, Relma-cel, RAK therapy, HPC, Cord Blood, Low-dose PRP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/auto-cd34-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Auto-CD34+ cells — Competitive Intelligence Brief

Auto-CD34+ cells (Auto-CD34+ cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine / Cardiovascular.

phase 3 Cell therapy Regenerative Medicine / Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

Auto-CD34+ cells (Auto-CD34+ cells) — Lisata Therapeutics, Inc.. Auto-CD34+ cells are autologous CD34+ hematopoietic stem cells mobilized and collected from a patient's own bone marrow or peripheral blood, then reinfused to promote tissue regeneration and repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Auto-CD34+ cells TARGET	Auto-CD34+ cells	Lisata Therapeutics, Inc.	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
cART	cART	LI Taisheng	marketed	CAR-T cell therapy	Tumor-associated antigen (specific target depends on formulation)
Relma-cel	Relma-cel	Shanghai Ming Ju Biotechnology Co., Ltd.	marketed	CAR-T cell therapy
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
HPC, Cord Blood	HPC, Cord Blood	National Marrow Donor Program	marketed	Cell therapy; hematopoietic stem cell transplant
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Auto-CD34+ cells — Competitive Intelligence Brief. https://druglandscape.com/ci/auto-cd34-cells. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab